永泰生物-B(06978.HK)擬認購投資基金
格隆匯1月4日丨永泰生物-B(06978.HK)發佈公吿,2020年12月31日,公司(作為認購人)與Tasly Bioscience Fund Limited(為其本身及以其作為投資基金普通合夥人的身份)訂立認購協議,內容有關認購事項。投資的資本承擔總額為1.568億港元,將由公司(作為有限合夥人)出資。
訂立認購協議時,Tasly Bioscience Fund Limited(作為普通合夥人)及Tasly Bioscience Fund Limited(作為投資基金有限合夥人(包括公司)的代理人)已於2020年12月31日訂立有限合夥協議,以規管彼等的關係並訂明(其中包括)投資基金的運作及管理方式。
公吿表示,集團不時挖掘潛在投資機遇。董事會認為此為集團透過認購事項間接從事投資醫療健康領域的良機。此外,董事會預計投資基金將進行的投資將為集團帶來投資回報及收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.